Format

Send to

Choose Destination
Int J Hyperthermia. 2018 Aug;34(5):512-517. doi: 10.1080/02656736.2017.1351627. Epub 2017 Jul 26.

Predictive value of peritoneal cancer index for survival in patients with mucinous peritoneal malignancies treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a single centre experience.

Author information

1
a Department of General, Visceral, and Transplantation Surgery and Department of General, Visceral, Vascular, and Thoracic Surgery, Campus Virchow and Mitte, Charité , Universitätsmedizin Berlin , Berlin , Germany.
2
b Institute of Pathology, Campus Mitte, Charité , Universitätsmedizin Berlin , Berlin , Germany.
3
c Biostatistics Unit , Berlin Institute of Health and Charité Universitätsmedizin Berlin , Berlin , Germany.

Abstract

OBJECTIVES:

This study investigated the correlation between the peritoneal carcinomatosis index (PCI) and patient outcome depending on the tumour type.

BACKGROUND:

Peritoneal surface malignancy (PSM) treatment depends on tumour type. Mucinous PSM (m-PSM) is associated with a better prognosis than non-mucinous PSM (nm-PSM). The PCI's predictive ability has not yet been evaluated.

METHODS:

We analysed 123 patients with PSM treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) between 2008 and 2015. The m-PSM group (n = 75) included patients with appendiceal cancer (n = 15), colorectal cancer (n = 21), or low-grade appendiceal mucinous neoplasm (n = 39); the nm-PSM group (n = 48) included patients with gastric (n = 18) or colorectal (n = 30) cancer. The PCI's predictive ability was evaluated by multiple Cox-proportional hazard regression analysis and Kaplan-Meier curves.

RESULTS:

The 5-year survival and PCI were higher in m-PSM patients (67.0%; 20.5 ± 12.1) than in nm-PSM patients (32.6%; p = 0.013; 8.9 ± 6.0; p < 0.001). Colorectal nm-PSM patients with PCI ≥16 had a worse 2-year survival (25.0%) vs. patients with PCI <16 (79.1%; log rank = 0.009), but no significant effect was observed in patients with m-PSM (66.7% vs. 68.1%; p = 0.935). Underlying disease (HR 5.666-16.240), BMI (HR 1.109), and PCI (HR 1.068) significantly influenced overall survival in all patients.

CONCLUSIONS:

PCI is prognostic in nm-PSM, but not in m-PSM. CRS and HIPEC may benefit not only patients with low PCI, but also those with high PCI and m-PSM.

KEYWORDS:

Cytoreductive surgery; HIPEC; mucinous adenocarcinoma; peritoneal cancer index

PMID:
28679331
DOI:
10.1080/02656736.2017.1351627
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center